Liu CW, et al. - Researchers investigated the dose-response impact of serum uric acid (SUA) levels on metabolic syndrome (MetS) and electrocardiographic left ventricular hypertrophy (LVH). They retrospectively collected and analyzed data from 18,932 Taiwanese individuals who had an annual health examination between January 1, 2016 and December 31, 2016, excluding those with systemic diseases or missing questionnaires. The primary study endpoints were the prevalence of MetS and LVH. They found that dose-response effects of SUA were associated with the prevalence of MetS and electrocardiographic LVH. In the overall study population, 29.5%, 9.4%, and 0.32% were estimated to be the prevalence rates of hyperuricemia, MetS, and LVH, respectively.